Preparation and characterisation of andrographolide niosomes and its anti-hepatocellular carcinoma activity. (June 2014)

• Record Type: Journal Article
• Authors: Tu, Y. S.; Sun, D. M.; Zhang, J. J.; Jiang, Z. Q.; Chen, Y. X.; Zeng, X. H.; Huang, D. E.; Yao, N.
• Is Part Of: Journal of microencapsulation. Volume 31:Number 4(2014:Jun.)
• Page Start: 307
• Page End: 316
• Publication Date: 2014-06
• Subjects: Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.3109/02652048.2013.843727
• Languages: English
• ISSNs: 0265-2048

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objective</italic>: In this study, a novel andrographolide (AG) preparation formulation, niosomes, was prepared to improve the bioavailability and tissue distribution of AG.</p> <p> <italic>Methods</italic>: The niosomal formulation of AG was prepared by film hydration/sonication method and tissue distribution was measured by liquid chromatography-mass spectrometry (LC-MS) method in mice, and anti-hepatocellular carcinoma (anti-HCC) activity was examined by MTT method in HepG2.</p> <p> <italic>Results</italic>: Entrapment efficiency, drug-loading ratio and average particle size of AG niosomes were 72.36%, 5.90% and 206 nm, respectively. The tissue distribution in mice demonstrated that the AG niosomes were absorbed in liver much more than the free AG. Furthermore, the anti-HCC activity in HepG2 cells showed that there was no significant difference between free AG and AG niosomes.</p> <p> <italic>Conclusion</italic>: The present results suggest that AG niosomes may have a significant potential of liver targeting, which is valuable in chemotherapy of HCC.</p> </abstract>